Catalyst's cocaine-addiction drug fails in a Phase II study
This article was originally published in Scrip
Executive Summary
Catalyst Pharmaceutical Partners' cocaine-addiction treatment CPP-109 (vigabatrin) has failed in Phase II trials. Preliminary results show that the US company's lead drug candidate did not meet its primary endpoint in trials – the number of CPP-109-treated subjects who were cocaine-free during the last two weeks of the treatment period was not statistically significantly larger than the number in the placebo arm.